COVID-19 Vaccine Updates

October 9, 2020

GNYHA is providing the following bulletin to keep member hospitals updated on the most recent information on the COVID-19 vaccine and related issues. We will continue to provide news and updates on the latest developments as appropriate.

DOHMH Webinar on COVID-19 Vaccine Provider Agreements

The New York City Department of Health and Mental Hygiene (DOHMH) will host a webinar today on the role providers will play in distributing and/or administering the COVID-19 vaccine. The webinar will detail the provider agreement form and DOHMH’s current plans for distribution. Hospitals are encouraged to register and participate here.

Finalized Framework for COVID-19 Distribution

The National Academies of Sciences, Engineering, and Medicine (NASEM) finalized the Framework for Equitable Allocation of COVID-19 Vaccine. The framework will guide national COVID-19 vaccine allocation and prioritization and is available on the NASEM website.

Pending COVID-19 Vaccine Data Submission Requirements

In the September National Healthcare Safety Network (NHSN) newsletter, the Centers for Disease Control and Prevention reported that COVID-19 vaccine(s) are expected to be available sometime in the fall of 2021. NHSN is developing reporting features for facilities to track COVID-19 vaccination data, including monitoring weekly vaccination data for health care personnel in both non-long-term care and long-term care facilities. Facilities will be notified when the reporting features are ready for use. The newsletter notes that while data submission is not currently required by the Centers for Medicare & Medicaid Services, NHSN encourages reporting as it will help identify gaps in COVID-19 vaccination and coverage.

Vaccine Trackers and Trial Databases

Both the World Health Organization and the New York Times have developed trial trackers that can help health care providers stay abreast of the latest developments in vaccine development. Additionally, the database lists all publicly and privately funded clinical trials related to COVID-19.